Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib

Paul La Rosée, Taiping Jia, Shadmer Demehri, Nicolai Härtel, Peter De Vries, Lynn Bonham, David Hollenback, Jack W. Singer, Junia V. Melo, Brian Druker, Michael W. Deininger

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Lysophosphatidic acid acyltransferase (LPAAT)-β catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-β induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-β as a potential drug target in neoplasia. Experimental Design: In this study, we investigated the effects of CT32228, a specific LPAAT-β inhibitor, on BCR-ABL-transformed cell lines and primary cells from patients with chronic myelogenous leukemia. Results: CT32228 had antiproliferative activity against BCR-ABL-postive cell lines in the nanomolar dose range, evidenced by cell cycle arrest in G 2-M and induction of apoptosis. Treatment of K562 cells with CT32228 led to inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, consistent with inhibition of mitogen-activated protein kinase signaling. Importantly, CT32228 was highly active in cell lines resistant to the Bcr-Abl kinase inhibitor imatinib. Combination of CT32228 with imatinib produced additive inhibition of proliferation in cell lines with residual sensitivity toward imatinib. In short-term cultures in the absence of growth factors, CT32228 preferentially inhibited the growth of granulocyte-macrophage colony-forming units from chronic myelogenous leukemia patients compared with healthy controls. Conclusion: These data establish LPAAT-β as a potential drug target for the treatment of BCR-ABL-positive leukemias.

Original languageEnglish (US)
Pages (from-to)6540-6546
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number21
DOIs
StatePublished - Nov 1 2006

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Line
Mitogen-Activated Protein Kinases
Apoptosis
Granulocyte-Macrophage Progenitor Cells
Phosphatidic Acids
Transformed Cell Line
Mitogen-Activated Protein Kinase 3
K562 Cells
Mitogen-Activated Protein Kinase 1
Growth
Cell Cycle Checkpoints
Pharmaceutical Preparations
Neoplasms
Intercellular Signaling Peptides and Proteins
Leukemia
Research Design
Phosphotransferases
Phosphorylation
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. / Rosée, Paul La; Jia, Taiping; Demehri, Shadmer; Härtel, Nicolai; De Vries, Peter; Bonham, Lynn; Hollenback, David; Singer, Jack W.; Melo, Junia V.; Druker, Brian; Deininger, Michael W.

In: Clinical Cancer Research, Vol. 12, No. 21, 01.11.2006, p. 6540-6546.

Research output: Contribution to journalArticle

Rosée, PL, Jia, T, Demehri, S, Härtel, N, De Vries, P, Bonham, L, Hollenback, D, Singer, JW, Melo, JV, Druker, B & Deininger, MW 2006, 'Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib', Clinical Cancer Research, vol. 12, no. 21, pp. 6540-6546. https://doi.org/10.1158/1078-0432.CCR-06-0140
Rosée, Paul La ; Jia, Taiping ; Demehri, Shadmer ; Härtel, Nicolai ; De Vries, Peter ; Bonham, Lynn ; Hollenback, David ; Singer, Jack W. ; Melo, Junia V. ; Druker, Brian ; Deininger, Michael W. / Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 21. pp. 6540-6546.
@article{37d7e46383184de8a01ff5eb7ea29eb0,
title = "Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib",
abstract = "Purpose: Lysophosphatidic acid acyltransferase (LPAAT)-β catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-β induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-β as a potential drug target in neoplasia. Experimental Design: In this study, we investigated the effects of CT32228, a specific LPAAT-β inhibitor, on BCR-ABL-transformed cell lines and primary cells from patients with chronic myelogenous leukemia. Results: CT32228 had antiproliferative activity against BCR-ABL-postive cell lines in the nanomolar dose range, evidenced by cell cycle arrest in G 2-M and induction of apoptosis. Treatment of K562 cells with CT32228 led to inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, consistent with inhibition of mitogen-activated protein kinase signaling. Importantly, CT32228 was highly active in cell lines resistant to the Bcr-Abl kinase inhibitor imatinib. Combination of CT32228 with imatinib produced additive inhibition of proliferation in cell lines with residual sensitivity toward imatinib. In short-term cultures in the absence of growth factors, CT32228 preferentially inhibited the growth of granulocyte-macrophage colony-forming units from chronic myelogenous leukemia patients compared with healthy controls. Conclusion: These data establish LPAAT-β as a potential drug target for the treatment of BCR-ABL-positive leukemias.",
author = "Ros{\'e}e, {Paul La} and Taiping Jia and Shadmer Demehri and Nicolai H{\"a}rtel and {De Vries}, Peter and Lynn Bonham and David Hollenback and Singer, {Jack W.} and Melo, {Junia V.} and Brian Druker and Deininger, {Michael W.}",
year = "2006",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-06-0140",
language = "English (US)",
volume = "12",
pages = "6540--6546",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Antileukemic activity of lysophosphatidic acid acyltransferase-β inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib

AU - Rosée, Paul La

AU - Jia, Taiping

AU - Demehri, Shadmer

AU - Härtel, Nicolai

AU - De Vries, Peter

AU - Bonham, Lynn

AU - Hollenback, David

AU - Singer, Jack W.

AU - Melo, Junia V.

AU - Druker, Brian

AU - Deininger, Michael W.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Purpose: Lysophosphatidic acid acyltransferase (LPAAT)-β catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-β induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-β as a potential drug target in neoplasia. Experimental Design: In this study, we investigated the effects of CT32228, a specific LPAAT-β inhibitor, on BCR-ABL-transformed cell lines and primary cells from patients with chronic myelogenous leukemia. Results: CT32228 had antiproliferative activity against BCR-ABL-postive cell lines in the nanomolar dose range, evidenced by cell cycle arrest in G 2-M and induction of apoptosis. Treatment of K562 cells with CT32228 led to inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, consistent with inhibition of mitogen-activated protein kinase signaling. Importantly, CT32228 was highly active in cell lines resistant to the Bcr-Abl kinase inhibitor imatinib. Combination of CT32228 with imatinib produced additive inhibition of proliferation in cell lines with residual sensitivity toward imatinib. In short-term cultures in the absence of growth factors, CT32228 preferentially inhibited the growth of granulocyte-macrophage colony-forming units from chronic myelogenous leukemia patients compared with healthy controls. Conclusion: These data establish LPAAT-β as a potential drug target for the treatment of BCR-ABL-positive leukemias.

AB - Purpose: Lysophosphatidic acid acyltransferase (LPAAT)-β catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-β induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-β as a potential drug target in neoplasia. Experimental Design: In this study, we investigated the effects of CT32228, a specific LPAAT-β inhibitor, on BCR-ABL-transformed cell lines and primary cells from patients with chronic myelogenous leukemia. Results: CT32228 had antiproliferative activity against BCR-ABL-postive cell lines in the nanomolar dose range, evidenced by cell cycle arrest in G 2-M and induction of apoptosis. Treatment of K562 cells with CT32228 led to inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, consistent with inhibition of mitogen-activated protein kinase signaling. Importantly, CT32228 was highly active in cell lines resistant to the Bcr-Abl kinase inhibitor imatinib. Combination of CT32228 with imatinib produced additive inhibition of proliferation in cell lines with residual sensitivity toward imatinib. In short-term cultures in the absence of growth factors, CT32228 preferentially inhibited the growth of granulocyte-macrophage colony-forming units from chronic myelogenous leukemia patients compared with healthy controls. Conclusion: These data establish LPAAT-β as a potential drug target for the treatment of BCR-ABL-positive leukemias.

UR - http://www.scopus.com/inward/record.url?scp=33751302125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751302125&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-0140

DO - 10.1158/1078-0432.CCR-06-0140

M3 - Article

C2 - 17085669

AN - SCOPUS:33751302125

VL - 12

SP - 6540

EP - 6546

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -